U.S. Semiconductors Stock News

If you are wondering whether NXP Semiconductors' current share price lines up with its underlying worth, you are not alone. This article is built to help you judge that for yourself using clear valuation checks. The stock last closed at US$222.13, with a 4.9% decline over the past 7 days and a 9.7% decline over the past 30 days, while its year to date return is 0.4% and its 1 year return is 4.4%, compared with 23.8% over 3 years and 24.9% over 5 years. Recent attention on NXP Semiconductors...

Uber Technologies (UBER) closed out FY 2025 with Q4 revenue of US$14.4b and basic EPS of US$0.14, alongside net income of US$296m, capping a year where trailing twelve month revenue reached US$52.0b and EPS came in at US$4.82. Over recent quarters, the company has seen revenue move from US$11.5b in Q1 2025 to US$13.5b in Q3 and then US$14.4b in Q4. Quarterly EPS shifted from US$0.85 in Q1 to US$3.18 in Q3 before landing at US$0.14 in the latest period, setting up a results season that puts...

Red Cat Holdings secured a contract to supply its Black Widow small unmanned aerial systems to a second Asia Pacific military ally. The agreement expands the international military adoption of the company’s NDAA compliant drone platform for tactical intelligence, surveillance and reconnaissance missions. This contract adds to Red Cat’s presence in the region and reinforces interest in U.S. manufactured small drone systems. For investors tracking Red Cat Holdings (NasdaqCM:RCAT), the new...

If you are wondering whether Roper Technologies is starting to look interesting at its current share price, this article will walk through what that might mean for you as an investor. The stock last closed at US$351.00, with returns of a 3.8% decline over 7 days, 19.6% decline over 30 days, 19.2% decline year to date, 39.4% decline over 1 year, 16.6% decline over 3 years, and 9.6% decline over 5 years. Recent news around Roper has focused on its positioning as a diversified software and...

GRAIL, Inc. previously submitted the final module of its Premarket Approval application to the U.S. FDA for its Galleri multi-cancer early detection test, drawing on performance and safety data from the large PATHFINDER 2 and NHS-Galleri trials and supported by a bridging analysis to the updated test version. This milestone builds on the FDA’s earlier Breakthrough Device designation and centers on extensive real-world screening data to assess Galleri’s clinical utility. We’ll explore how...

If you are trying to work out whether Materion’s share price still offers value at its current level, the key question is how that price lines up against what the business may be worth. The stock last closed at US$145.83, with returns of 2.8% over 7 days, 8.3% over 30 days, 13.5% year to date, 43.6% over 1 year, 73.7% over 3 years and 115.6% over 5 years. This naturally raises questions about how much of the story is already reflected in the price. Recent news coverage has focused on...

If you are wondering whether Aptiv's current share price lines up with its underlying value, you are not alone. This article is designed to help you frame that question clearly. Aptiv's stock last closed at US$79.72, with returns of 1.1% over 7 days, a 3.5% decline over 30 days, 1.6% year to date, a 25.6% gain over 1 year, and declines of 31.3% and 48.2% over 3 and 5 years respectively. Taken together, these figures give a mixed signal about growth potential and risk perception. Recent...

Structure Therapeutics (NasdaqGM:GPCR) has advanced its lead obesity candidate GSBR-1290 into phase 2 clinical trials as an oral treatment. The move comes as the company draws increased attention for targeting the obesity market with a pill-based approach rather than injectables. Analyst optimism and early discussion about potential takeovers have put fresh focus on the stock. Structure Therapeutics, trading under NasdaqGM:GPCR, is drawing fresh interest after pushing GSBR-1290 into phase...

If you are trying to figure out whether Molina Healthcare's share price reflects its true worth, the starting point is understanding how its current market price compares with a range of valuation checks. The stock last closed at US$176.84, with returns of a 4.4% decline over 7 days, 4.3% decline over 30 days, 0.9% decline year to date, 38.0% decline over 1 year, 41.3% decline over 3 years, and 18.2% decline over 5 years, which may have shifted how investors see its potential and its...

Tennant Company set the date for its 2026 annual meeting of shareholders. The company also announced the deadline for shareholders to nominate director candidates for the 2026 board election. The update outlines the timetable that will guide board nominations and voting for NYSE:TNC. Tennant, trading on the NYSE under ticker NYSE:TNC, recently closed at $80.84. The stock is up 5.5% over the past week, 5.0% over the past month, and 9.3% year to date, while showing a 4.1% decline over the...

To the annoyance of some shareholders, Doximity, Inc. ( NYSE:DOCS ) shares are down a considerable 27% in the last...

BioNTech (NasdaqGS:BNTX) has created a new Chief People Officer role. Kylie Jimenez has been appointed to the position, effective immediately. The move is tied to BioNTech’s goal of becoming a multi product oncology leader beyond its COVID 19 work. BioNTech, known widely for its COVID 19 vaccine partnership, is working to build a broader pipeline in oncology and other therapeutic areas. The new Chief People Officer role indicates that leadership views talent, organizational design, and...

Iridium Communications: Recent Returns and Business Profile Iridium Communications (IRDM) has been drawing attention after a mixed stretch in its share price, with a 1 day return showing a 1.9% decline, contrasted with positive moves over the month and the past 3 months. The company runs a global mobile satellite communications business from its headquarters in McLean, Virginia, serving commercial customers, governments, non governmental organizations, and consumers with voice, data,...

If you have ever wondered whether Shake Shack's current share price reflects what you are actually getting as an investor, you are not alone. The stock recently closed at US$93.07, with returns of 5.7% over 7 days, 3.6% over 30 days, 11.5% year to date, 64.1% over 3 years, and a 19.2% decline over 1 year. Taken together, this gives a mixed picture of how the market has been reassessing it over different timeframes. Recent coverage has focused on Shake Shack as a branded fast casual player...

Q3 results and AI platform upgrade put Globant (GLOB) in focus Globant (GLOB) is back on investors’ radar after Q3 2025 revenues came in slightly above the top end of guidance, alongside strong free cash flow and an October upgrade to its Enterprise AI platform. See our latest analysis for Globant. Despite the Q3 beat and the Enterprise AI 2.3 upgrade, Globant’s recent share price momentum has been weak, with a 30 day share price return of a 17.64% decline and a 1 year total shareholder...

The New York Times (NYT) closed out FY 2025 with Q4 revenue of US$802.3 million and basic EPS of US$0.80, compared with US$719.5 million of revenue and EPS of US$0.75 in the prior year’s Q4, pointing attention squarely to how efficiently the business is turning its top line into profit. Over the past six quarters, the company has seen quarterly revenue move from US$633.6 million in Q3 2024 to US$694.1 million in Q3 2025 and then to US$802.3 million in Q4 2025, while basic EPS ranged from...

Webull (BULL) has drawn fresh attention after rolling out sports prediction markets through its partnership with Kalshi, giving users event based contracts tied to outcomes like the Big Game and economic indicators. See our latest analysis for Webull. The excitement around prediction markets and Webull’s upcoming appearance at the Fintech & DATS Investor Conference comes against a weak run for the stock, with a 30 day share price return of 32.72% and a 1 year total shareholder return of...

UiPath, Inc. ( NYSE:PATH ) shares have had a horrible month, losing 30% after a relatively good period beforehand. The...

As you might know, Broadridge Financial Solutions, Inc. ( NYSE:BR ) just kicked off its latest quarterly results with...

Sempra subsidiaries Southern California Gas Co. and San Diego Gas & Electric have petitioned California regulators to drop a 5% hydrogen blending demonstration requirement. The filing argues that existing research and operational data are sufficient to assess low level hydrogen blending safety without new pilot projects. The request targets rules that would have required utilities to complete demonstration projects before regulators consider a systemwide hydrogen blending standard. Sempra,...

Whirlpool (NYSE:WHR) has been named to TIME's inaugural "America’s Most Iconic Companies" list. The company is the only home appliance brand included, recognized for its cultural impact and commitment to U.S. manufacturing. This recognition highlights Whirlpool’s long history in American households and its continued domestic production footprint. For investors tracking Whirlpool at a share price of $85.09, this recognition arrives alongside mixed recent return data. The stock is up 10.6%...

If you have ever wondered whether Manchester United's stock price matches your view of the club's global stature, this is a good moment to look closely at what the market is actually paying for the shares. The stock recently closed at US$16.99, with a 7.7% return year to date, a 5.9% return over 1 year, a 6.4% gain over 30 days, but a 4.4% decline over the last week and a 33.1% decline over 3 years, which gives a mixed picture for investors weighing potential and risk. Recent coverage has...

FDA accepts Exelixis' New Drug Application for zanzalintinib plus atezolizumab in metastatic colorectal cancer. The application is based on pivotal trial data for patients with advanced disease. This step moves the investigational combination closer to potential commercial use in the United States. For investors watching NasdaqGS:EXEL, this FDA filing milestone is an important datapoint in the company’s oncology pipeline. Exelixis focuses on cancer therapies, and colorectal cancer is a...

If you are wondering whether Janus Henderson Group's current share price still makes sense, you are not alone. Many investors are asking if the stock offers solid value at today's level. The shares last closed at US$48.19, with returns of 0.5% over 7 days, 0.3% over 30 days, 0.9% year to date and 9.3% over 1 year, while 3-year and 5-year returns sit at very large levels close to a 2x gain. Recent attention on Janus Henderson Group has been shaped by coverage of its position in the global...